<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066555</url>
  </required_header>
  <id_info>
    <org_study_id>FIL-RougeBIO</org_study_id>
    <nct_id>NCT05066555</nct_id>
  </id_info>
  <brief_title>Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial</brief_title>
  <acronym>FIL-RougeBIO</acronym>
  <official_title>Circulating Tumor DNA Genotyping for Biological Monitoring of Patients With Advanced-stage Classical HL Receiving Upfront ABVD-based Chemotherapy. An Ancillary Study to the FIL-Rouge Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, non-interventional, biological study ancillary to FIL-Rouge&#xD;
      clinical trial (NCT03159897) enrolling patients affected by Advanced-stage Hodgkin Lymphoma,&#xD;
      ABVD-based upfront treatment in 19 centers in Italy part of Fondazione Italiana Linfomi.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FIL-Rouge design provides an ideal environment for validating the liquid biopsy in&#xD;
      Classical Hodgkin lymphoma (cHL), since one arm of the study will utilize a PET/CT-adapted&#xD;
      strategy (Positron Emission Tomography/Computed Tomography)for treatment, while the second&#xD;
      arm will be devoid of any PET/CT-adaptation of therapy. Also, estimating prospectively&#xD;
      differences in residual disease between the two study arms of the FIL-Rouge will provide an&#xD;
      important biologic tool to validate the concept of dose-intensification within the ABVD&#xD;
      therapeutic platform.&#xD;
&#xD;
      This study aims at the prospective validation of the concept of the liquid biopsy as a&#xD;
      biomarker for disease response assessment in cHL. The patients enrolled in the FIL-Rouge&#xD;
      clinical trial at the centers participating in this study and consenting to the biological&#xD;
      study FIL-RougeBIO will be considered for this study. After providing written informed&#xD;
      consent, relevant patients will be evaluated for detecting cancer gene mutations in ctDNA&#xD;
      (Circulating Tumor DNA) for measuring residual disease. All clinical data useful for data&#xD;
      analyses of this study will derive from the FIL-Rouge clinical trial.&#xD;
&#xD;
      Given the non-interventional design of the study, project participants will not have&#xD;
      immediate potential benefits.The enrollment in FIL-RougeBIO will parallel the original&#xD;
      protocol until reaching the 500 programmed patients. The results of this study could benefit&#xD;
      future patients with the same condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 76 months</time_frame>
    <description>Complete Response Rate (CRR) is defined as the proportion of patients achieving a Complete Remission (CR) at the end of treatment;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of Circulating tumor DNA (ctDNA) analysis versus interim PET/CT (Positron Emission Tomography/Computed Tomography)</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 76 months</time_frame>
    <description>Diagnostic accuracy of Circulating tumor DNA (ctDNA) analysis versus interim PET/CT (sensitivity, specificity, positive predictive value, negative predictive value, positive and negative likelihood ratios accuracy); The endpoint will be evaluated through specific timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) with at least three years of follow up</measure>
    <time_frame>The endpoint will be assessed from the beginning of the study up to 76 months</time_frame>
    <description>PFS is defined as the interval elapsing from randomization until lymphoma progression/relapse or death as a result of any cause.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Advanced-stage Hodgkin Lymphoma patients (1)</arm_group_label>
    <description>All patients will be accrued by investigators from the 19 best recruiting centers in the FIL-Rouge clinical trial. Patients had undergone to ABVD-based upfront treatment in FIL-Rouge trial (Comparator arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced-stage Hodgkin Lymphoma patients (2)</arm_group_label>
    <description>All patients will be accrued by investigators from the 19 best recruiting centers in the FIL-Rouge clinical trial. Patients had undergone to ABVD-based upfront treatment in FIL-Rouge trial (Experimental arm).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples will be collected in Cell-Free DNA BCT tubes before treatment start,&#xD;
      at the interim PET/CT (Positron Emission Tomography/Computed Tomography), at the end of&#xD;
      treatment assessment, and at the time of disease progression/relapse and will be analyzed for&#xD;
      ctDNA (Circulating tumor DNA) and gDNA (genomic DNA) genotyping and for cytokines and&#xD;
      chemokines levels.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligibility criteria for participation in this study require:&#xD;
&#xD;
          -  Enrollment in the FIL-Rouge clinical trial;&#xD;
&#xD;
          -  Evidence of signed informed consent for the biological FIL-RougeBIO study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: FIL ROUGE INCLUSION CRITERIA&#xD;
&#xD;
          -  Histologically confirmed classical HL&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  Age 18-60 years&#xD;
&#xD;
          -  Ann Arbor stage IIB with extranodal involvement and/or bulk, III and IV&#xD;
&#xD;
          -  At least one target PET-avid bidimensionally assessable lesion&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &lt;= 2&#xD;
&#xD;
          -  Adequate organ and marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1,0 x109/L, platelets &gt;75 x109/L&#xD;
&#xD;
               -  Total bilirubin &lt;2 mg/dl without a pattern consistent with Gilbert's syndrome&#xD;
&#xD;
               -  Aspartate Transaminase and Alanine Transaminase (AST/ALT) &lt;3 X institutional&#xD;
                  Upper Limits of Normality (ULN)&#xD;
&#xD;
               -  Creatinine within normal institutional limits or creatinine clearance &gt;50&#xD;
                  mL/min/1.73 m2&#xD;
&#xD;
          -  Females of childbearing must have a negative pregnancy test under medical supervision&#xD;
             even if patients had been using effective contraception&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Signed (or legally acceptable representatives must sign) informed consent indicating&#xD;
             that patients understand the purpose of and procedures required for the study and are&#xD;
             willing to participate in the study.&#xD;
&#xD;
          -  Access to PET-CT (Positron Emission Tomography/Computed Tomography) scans facilities&#xD;
             qualified by FIL&#xD;
&#xD;
        Exclusion Criteria: FIL ROUGE EXCLUSION CRITERIA&#xD;
&#xD;
          -  Nodular Lymphocyte Predominant HL&#xD;
&#xD;
          -  Ann Arbor stage IIB without extranodal involvement and/or mediastinal bulky&#xD;
&#xD;
          -  Prior chemotherapy or radiation therapy&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Known hypertension, cardiac arrhythmia, conduction abnormalities, ischemic&#xD;
             cardiopathy, left ventricular hypertrophy or left ventricular ejection fraction (LVEF)&#xD;
             â‰¤50% at echocardiography.&#xD;
&#xD;
          -  Abnormal QTc interval prolonged (&gt;450 msec in males; &gt;470 msec in women)&#xD;
&#xD;
          -  Diffusion lung capacity for CO (DLCO)and/or Forced expiratory volume in the 1st second&#xD;
             (FEV1) tests &lt;50% of predicted not due to mediastinal compression or parenchymal&#xD;
             lymphoma&#xD;
&#xD;
          -  Known cerebral or meningeal disease (HL or any other etiology)&#xD;
&#xD;
          -  Prior history of malignancies unless the patient has been free of the disease for five&#xD;
             years. Exceptions include the following: basal cells carcinoma of the skin, squamous&#xD;
             cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the&#xD;
             breast and prostate cancer with the TNM stage of T1a or T1b&#xD;
&#xD;
          -  Uncontrolled infectious disease&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positivity or active infectious A, B or C&#xD;
             hepatitis. HBsAg-negative patients with anti-HBc (Hepatitis B core) antibody and can&#xD;
             be enrolled provided that Hepatitis B Virus (HBV)-DNA are negative and that antiviral&#xD;
             treatment with nucleos(t)ide analogs is provided (Lamivudine)&#xD;
&#xD;
          -  Uncompensated diabetes&#xD;
&#xD;
          -  Refusal of adequate contraception&#xD;
&#xD;
          -  Any medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pinto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Ematologia, Istituto Nazionale Tumori, Fondazione Pascale, IRCCS, Napoli, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia - Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - UOC Ematologia Oncologica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio ospedaliero &quot;A. TORTORA&quot; - U.O. Onco-ematologia</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria della Misericordia - Ematologia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini - U.O. di Ematologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas - U.O. Ematologia</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - S.C.Ematologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>ABVD treatment</keyword>
  <keyword>ancillary</keyword>
  <keyword>ctDNA</keyword>
  <keyword>cHL</keyword>
  <keyword>FIL-Rouge</keyword>
  <keyword>PFS</keyword>
  <keyword>Response Rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

